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intellectual	 labour	 invested	 in	 the	manufacture	of	biological	 inventions.	By	examining	
how	the	creators	of	engineered	mice	strains	deposited	at	the	Jackson	Laboratory	have	
utilised	 patent,	 I	 here	 explore	 the	 paradoxical	matter	 of	 why	 they	 have	 not	 asserted	
their	 rights	 in	 the	way	 anticipated	 by	 patent	 advocates.	 The	 emergence	 of	 new	 open	
source	 economies	 in	 mammalian	 genetic	 resources	 (the	 Mouse	 Academic	 Commons)	
has	 served	 to	 valorise	 collaborative	 working	 and	 iterative	 forms	 of	 experimentation.	
Engineered	 mouse	 strains	 are,	 in	 this	 context,	 best	 conceived	 of	 as	 an	 experimental	
space	 or	 biological	 commons	 open	 to	 re-invention	 by	 all.	 The	 key	 issue	 of	 how	
individual	donors	can	protect	the	integrity	of	their	donated	‘works’	and	capitalize	on	the	
intellectual	 labour	 invested	 in	 their	 creation	 remains,	 however,	 largely	 unexplored.	
Here	 I	 argue	 that	 value	 lies	 not	 in	 the	model	mouse	 or	 strain	 itself,	 but	 rather	 in	 the	
experimental	 techniques	 that	 assure	 its	 continued	 genetic	 integrity;	 and	 demonstrate	
how	process	patents	 and	 trademark	are	 together	deployed	 to	assure	 the	 reliability	of	
the	 personality,	 identity,	 and	 reputation	 of	 the	 protected	 strains;	 and	 with	 it	 the	
economic	viability	of	a	biotechnological	commons.		
	





































                                                
1 As discussed in Singh, K. K. (2014). Biotechnology and Intellectual Property Rights: Legal and Social 
Implications. Springer. P. 28.  
2 https://supreme.justia.com/cases/federal/us/447/303/case.html 
3The USPTO granted a patent number US4736866 to Harvard College claiming, “a transgenic non-human 























































                                                
4 The Jackson Laboratory, situated in Bar Harbour, Maine, USA maintains one of the world’s largest not for 















of	 complex	 and	 sometimes	 counterintuitive	 reasons.	 I	 therefore	 begin	my	 analysis	 by	
examining	 how	 those	 researchers	who	 did	 hold	 patents	 utilized	 those	 rights.	 Patents	
have	 been	 viewed,	 historically,	 as	 a	 vehicle	 through	 which	 scientist	 inventors	 might	
secure	reach	through	rights	and	royalties	for	commercial	products	developed	from	their	
protected	strains,	however,	many	did	not	exercise	these	rights	to	that	end.	What	could	




ontological	 standing	of	mice	models.	Here	 I	 suggest	 that	 JAX®Mice	mouse	models	are	
                                                                                                                                                  
it distributes in over 100 countries to academic, pharmaceutical and biotechnological researchers and 
corporations.  





perhaps	 best	 understood	 as	 collectively	 authored	 performative	 works	 rather	 than	
products	per	se.	Indeed,	as	I	argue	here,	the	engineered	mouse	itself	has	become	a	kind	
of	 biological	 commons	 the	 true	 value	 of	 which	 is	 only	 fully	 realized	 through	
collaborative	circulation	and	use.	Patent:	the	extension	of	exclusive	monopolistic	rights	
of	 ownership	 and	 control	 can,	 in	 such	 circumstances,	 have	 a	 deadening	 effect	 on	 the	
generation	of	knowledge	and	capital.	In	the	brave	new	world	of	the	biological	commons	
the	primary	work	of	 IPR	 instruments	 is	perhaps	not	 to	deliver	royalties	 to	 ‘inventors’	
but	 rather,	 as	 I	 propose	here,	 to	 protect	 the	personality,	 identity,	moral	 standing	 and	
foremostly	reputation	of	protected	strains.	As	I	argue	in	the	third	section,	this	work	is	




creation	 in	 this	 emergent	 bioeconomy.	 To	 contextualize	 this	 analysis,	 I	 begin	 by	





Over	 the	 past	 century,	 the	mouse	 has	 developed	 into	 the	 premier	mammalian	model	
system	 for	 genetic	 research.	 At	 a	 molecular	 level	 mice	 and	 humans	 are	 remarkably	
similar	with	99%	of	human	genes	having	mouse	counterparts	or	homologues.	For	these	
reasons,	 as	 Rader	 argues	 (2004:260),	 “it	 was	 the	 first	 mammal	 chosen	 as	 a	 ‘model	




affect	 the	 immune,	 endocrine,	 nervous,	 cardiovascular	 and	 other	 systems,	 including	
cancer,	 hypertension,	 diabetes,	 osteoporosis	 and	 glaucoma.	 Other	 diseases	 that	 only	
afflict	 humans	 such	 as	 cystic	 fibrosis	 and	 Alzheimer's	 can	 be	 induced	 in	 mice	 by	
manipulating	their	genomes.	This	can	be	achieved	by	either	inbreeding	strains	of	mice	






The	biological	properties	of	 the	mouse:	 tameness	and	user	 friendliness,	 its	 small	 size,	
high	natural	mutability	and	fecundity	make	it	an	ideal	tool	for	experimental	biomedical	
research	 that	 requires	 large	 sample	 sets	 or	 involves	 the	 observation	 of	 generational	
patterns	of	genetic	and	phenotypical	expression.	Previous	work	(Löwy	and	Gaudillière	
1998,	 Rader,	 2004;	 Kirk,	 2008)	 has	 outlined	 the	 enormously	 complex	 social	 and	
material	 practices	 that	 have	 attended	 the	 transformation	 of	 the	 mouse	 from	 ‘wild’	
creature	to	highly	standardised	model	organism	capable	of	being	reproduced	with	the	
least	 possible	 variability	 across	 generations.	 As	 Ankeny	 and	 Leonelli	 have	 noted	
(2011:316)	processes	of	standardisation	and	the	establishment	of	‘pure	lines’	are	key	to	
genetic	 research	as	 they	allow	“features	valued	by	researchers	 to	be	 reproduced	with	
the	 least	 possible	 variability	 across	 generations”	 thus	 providing	 “a	 detailed	 genetic	
account	of	the	standard	organisms	in	terms	of	sequence,	gene	function	and	phenotype”.	
In	the	post	genomic	era	however,	the	ability	or	even	the	desirability	of	making	mouse	






its	 research	 staff)	 and	 its	 founder	 Clarence	 Cook	 Little	 played	 a	 central	 role	 in	 the	
production	of	the	first	genetically	standardized	mice	and	inbred	mouse	strains	including	
spontaneous	 and	 induced	 mutants.	 Driven	 initially	 by	 Little’s	 personal	 interests	 in	
mammalian	genetics	and	cancer	research,	 the	demand	 for	stabilised	 lines	on	which	 to	
perform	 consistent	 comparative	 work	 with	 the	 least	 possible	 variability	 began	 to	
increase	 as	 their	 experimental	 utility	 was	 confirmed.	 Much	 has	 been	made	 in	 recent	
accounts	of	 the	scaling	up	of	mutant	mouse	production	 that	consequently	occurred	at	
JAX	 during	 the	 pre-war	 Fordist	 period.	 Rader	 for	 example,	 reminds	 us	 that	 JAX’s	
facilities	became	cast	in	the	public	imagination	as	‘mouse	factories’	where	strains	were	
‘mass	produced’,	a	notion	that	greatly	appealed	to	its	corporate	funders	such	as	Detroit	
car	 manufacturers,	 The	 Hudson	 Motor	 Car	 Company	 (Rader,	 2004:20).	 Corporate	
embrace	 of	 intellectual	 property	 rights	 and	 the	 resultant	 increase	 in	 the	 patenting	 of	




This	 narrative	 gained	 purchase	 throughout	 the	 post	 war	 period	 as	 techniques	 for	
molecular	 level	 manipulation	 were	 refined	 and	 as	 researchers	 and	 their	 financial	
backers	 sought	 new	 means	 to	 capitalise	 on	 their	 investments	 in	 research.	 The	
conception	that	engineered	organisms	are	an	embodiment	of	a	set	of	ideas	about	how	to	
re-design	nature	manifest	 in	 a	material	 form,	 crystallised	during	 the	 late	1960s	along	
with	 the	concomitant	assertion	 that,	as	 ‘inventions’	 they	ought	rightfully	be	subject	 to	




engineered	 bacterium	 as	 a	 “non-naturally	 occurring	 manufacture	 or	 composition	 of	
matter”,6	 precipitated	 the	 patenting	 of	 higher	 forms	 of	 life	 culminating	 in	 Harvard’s	
patent	 for	 their	 ‘man-made	 model	 system	 for	 the	 study	 of	 cancer’,	 the	 OncoMouse	
(Kevles,	2002:	84)	7.			
	
Whilst	 Harvard	 held	 the	 patent	 they	 were	 also	 obliged	 to	 fulfil	 obligations	 to	 their	
funders,	 the	 Dupont	 Corporation,	 which	 had	 invested	 six	 million	 dollars	 into	
development	 of	 the	 mouse.	 This	 investment	 was	 to	 be	 returned	 by	 giving	 Dupont	
exclusive	 rights	 to	 license	 and	 extract	 royalties	 from	 applied	 uses	 of	 the	 mouse.	 In	
anticipation	 of	 forthcoming	 marketisation	 and	 sales	 the	 mouse	 was	 also	 given	 a	
registered	 trademark:	 OncoMouse®.	 However,	 Paul	 Clark,	 Harvard’s	 principle	 patent	
counsel	made	 clear	 at	 the	 time	 that	 he	 believed	 that	 “the	work’s	most	 apparent	 and	
compelling	manifestation	was	 the	 animal	 itself”	 (my	 italics).	 He	was	 also	 certain	 that	
method	patents	 on	 the	means	of	 production	 for	 the	mouse	would	not	 suffice:	 “that	 it	
was	better	to	protect	the	product	as	well	as	the	processes	used	to	produce	it,	otherwise	
competitors	using	different	processes,	could	develop	similar	products”	(cited	in	Kevles,	
2002:84).	 It	 is	 worth	 noting	 here	 the	 clear	 assertion	 that	 it	 is	 the	 mouse	 itself	 that	
constitutes	the	intellectual	property	that	patent	is	called	upon	to	protect.			
	
                                                
6 It is important to note that the fundamental principle established in the Diamond Vs. Chakrabarty case: that the 
mere isolation of genes was sufficient intellectual labour to warrant patent protection was later overturned in the 
landmark case Association for Molecular Pathology Vs. Myriad Genetics (2013).  
7The OncoMouse patent was later subject to considerable contestation in European and Canadian jurisdictions 
on the grounds that its passage would be contrary to "ordre public" or morality.	The Supreme Court of Canada 
rejected a patent on OncoMouse by a majority in 2002 after determining that the mouse did not constitute a 
‘manufacture or composition of matter within the meaning of invention’. The patent has since been revoked or 
expired in several jurisdictions including the US and Europe.  
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Deeply	 held	 concerns	 about	 the	 implications	 that	 patenting	 could	 have	 for	 delimiting	
access	to	vital	mouse	strains	erupted	publicly	at	the	Mouse	Molecular	Genetics	meeting	
at	 Cold	 Harbour	 in	 1992.	 At	 this	 meeting	 Harold	 Varmus’s	 then	 Director	 of	 the	 NIH	
made	an	impassioned	plea	for	maintaining	unfettered	academic	access	to	model	mice	to	
advance	biomedical	 research	 for	 the	public	or	 common	good	 (Paigen,	1995).	This	 call	
was	taken	up	by	Dr.	Kenneth	Paigen,	then	Director	of	JAX	who	announced	that	the	lab	
was	 prepared	 to	 act	 as	 a	 repository	 for	 all	 new	 strains	 of	 inbred	 and	 genetically	
modified	mice	 generated	 in	 the	US.	 The	 philosophy	 of	 the	 repository8,	which	 became	
known	thereafter	as	the	Induced	Mutant	Resource	or	IMR,	was	to	accept	all	genetically	
engineered	 mice,	 whether	 patented	 or	 not,	 and	 to	 then	 distribute	 them	 for	 use	 to	
academic	 institutions,	 pharmaceutical	 and	 biotech	 companies	worldwide	 for	 research	
purposes,	 unfettered	 by	 onerous	 licensing	 requirements	 such	 as	 reach	 through	 or	
royalty	rights.	Individual	researchers	who	developed	mutant	mice	strains	in	the	late	90s	
and	 early	 2000s	 in	 the	 US	 had	 particular	 interests	 in	 ensuring	 that	 their	 mice	 were	
deposited	 for	 distribution	 with	 a	 central	 well	 organised	 repository.	 Although	 many	
strains	 would	 ultimately	 have	 only	 limited	 distribution	 they	 nevertheless	 remain	
crucially	 important	 to	 particular	 biomedical	 research	 projects	 and	 all	 researchers	
wished	to	make	them	available	to	maximise	their	utility	to	any	prospective	user.		
	
Researchers	who	were	 unable	 to	 shoulder	 the	 costs	 of	maintaining,	 characterising	 or	
distributing	 these	 strains	 themselves	 appreciated	 JAX’s	 willingness	 to	 take	 on	 these	
responsibilities	 for	 them.	However,	whilst	 JAX	 could	 charge	 a	 fee	 for	 reproducing	 the	
mouse	 itself	on	demand;	 this	alone	could	not	capture	 the	 full	value	of	 the	animal	as	a	
                                                
8 Repository mice include inbred strains, strains and stocks carrying either induced or spontaneous mutations, 
strains and stocks carrying chromosomal aberrations, recombinant inbred strains, recombinant congenic strains, 
chromosome substitution (consomic) strains, and congenic strains (strains with selected alleles maintained on 








for	 their	 subsequent	 use,	 this	 was	 certainly,	 at	 that	 time,	 the	 wider	 normative	
presumption	 about	how	animal	patenting	 should	work.	To	 test	 this	 theory	 JAX’s	 then	







The	 results	 showed	 that	 some	 70	 researchers	 had	 contributed	 unpatented	 mouse	
strains	 to	 the	 repository.	 Unsurprisingly,	 none	 had	 sought	 to	 impose	 any	 “reach-
through”,	internal	breeding	or	field-of-use	restrictions	for	academic	recipients	although	
most	(92.8%)	had	required	for-profits	to	sign	a	licencing	agreement	of	some	kind.	What	
their	research	also	revealed	however,	was	 that	none	of	 the	donors	of	patented	 strains	
had	 sought	 to	 impose	 any	 substantive	 restrictions,	 reach	 through	 rights	 or	 royalty	
provisions	 on	 prospective	 users	 either.	 In	 other	 words,	 as	 Einhorn	 and	 his	 team	
concluded	 “licenses	were	nearly	universally	 free	 from	any	 substantive	 restrictions	 on	
downstream	academic	research,	whether	or	not	the	mouse	strain	was	patented,	 leaving	












To	 understand	why	 patent	 proved	 to	 have	 so	 little	 bearing	 on	 negotiations	 over	 the	
prospective	circulation	and	use	of	 these	model	mice	 it	 is	essential	 to	understand	how	
model	 mice	 have	 been	 conceptualised	 ontologically;	 characterised	 and	 employed	 in	
research	 settings	 and	 how	 the	 dynamics	 of	 their	 production	 has	 evolved	 over	 time.	
Unlike	 other	 early	 twentieth	 century	 examples	 of	 industrial	 inventorship	 and	
manufacture,	 attempts	 to	 create	 genetically	 stable	 inbred	 mouse	 colonies	 were	 not	
singular	 endeavours	but	 rather	 relied	 from	 the	beginning	on	 sustained	 collaborations	
between	 a	 highly	 variegated	 community	 of	 ‘mouse	 fanciers’.	 Ontological	 distinctions	
between	 ‘scientific’	 breeders	 and	 local	 dilettantes	 were	 not	 initially	 as	 formally	










As	 Rader	 (2004:	 32-3)	 notes,	 Clarence	 Little	 and	 colleagues	 drew	 heavily	 on	 stocks	
generated	by	 these	 fanciers	 as	 they	had	 already	 “essentially	 routinized	 the	 activity	 of	
mouse	breeding	in	captivity	well	before	scientists	became	interested	in	the	mouse	as	an	




such	colonies	were	 imported	 into	 Jackson	becoming	there	concentrated	and	stabilised	
they	 are	 best	 understood	 both	 then	 and	 now	 not	 as	 the	 manufactured	 outputs	 of	






















It	 is	 significant	 that	 Sennett	 here	 contemporises	 understandings	 of	 what	 constitutes	
craftsmanship	by	relocating	that	tradition	within	high	tech	industries	such	as	computer	
software	 generation,	 as	 practised	 by	 the	 Linux	 community.	 In	 explicating	 the	 social	
dynamics	 that	 underpin	 such	 work	 Sennett	 goes	 so	 far	 as	 to	 argue	 that	 “good	
craftsmanship	implies	socialism”	that	it	“depends	on	curiosity,	tempers	obsession;	that	
craftwork	 turns	 the	 craftsman	 outwards,”	 into	 continued	 engagement	 with	 other	
specialists	 within	 and	 beyond	 local	 workshops	 (2008:	 288).	 Mouse	 researchers	 later	










researchers	 located	 in	 the	US	 and	 beyond	 not	 responded	 by	 sending	 back	 to	 Jackson	





researchers	 generating	 new	 strains	 (OECD,	 2001:	 20).	 Maintaining	 access	 to	 these	
resources	became	a	key	modality	of	life	within	the	mouse	genetics	research	community	
an	 ethos	 that	 underpinned	 their	 public	 commitment	 to	 the	 generation	 of	 one	 of	 the	
world’s	 first	biotechnological	 commons:	 their	Mouse	Academic	Research	Commons	or	
Mouse	 Commons.	 The	 question	 of	 how	 to	 defend	 access	 to	 these	 resources	 was	 a	




























Over	 time	 however,	 JAX	 researchers	 began	 to	 recognise	 that	 the	 creative	 and	 thus	
economically	generative	potential	of	 the	alterations	that	were	being	made	to	 the	mice	
could	 only	 be	 fully	 realised	 when	 they	 were	 collaboratively	 witnessed,	 shared	 and	
cooperatively	 refined.	 Exclusion,	 even	 when	 performed	 defensively,	 did	 not	 facilitate	
this	end.	A	genuinely	comprehensive	and	widely	accessible	mouse	commons	could	only	
emerge	 if	 the	 “open	 sourcing”	 of	 mammalian	 genetic	 resources	 were	 to	 become	 a	
reality.	The	term	‘open	source’	is	drawn	deliberately	from	the	informational	domain	in	
order	 to	 point	 up	 parallels	 between	 the	 digital	 informational	 economy	 and	 the	
bioeconomy	in	relation	to	their	use	of	what	might	be	termed	foundational	programmatic	
resources.	 These	 are	 resources	 (whether	 informational	 or	 corporeal)	 that	 can,	 at	 a	
fundamental	 level,	be	creatively	and	 iteratively	re-programmed	to	produce	from	them	






are	 encouraged	 to	 access	 it	 without	 the	 restrictions	 of	 a	 patent	 regime	 in	 order	 to	
produce	 from	 it,	 other	 products	 via	 what	 Castells	 would	 refer	 to	 as	 a	 ‘cumulative	
17 
 
feedback	 loop’.	 	 In	 the	 biological	 realm	 these	 kinds	 of	 foundational	 programmatic	




Early	 models	 that	 promoted	 open	 access	 include	 the	 Bermuda	 Principles	 that	
established	rules	for	the	rapid	accessioning	and	release	of	the	Human	Genome	Project	
DNA	 sequence	 data	 and	 the	 agreement	 by	 drug	 companies	 in	 the	 Single	 Nucleotide	
Polymorphism	Consortium	to	deposit	their	bio-information	in	the	public	domain.	Each	
realize	 the	 concept	of	 ‘open	source	biology’	by	making	bio-informational	 technologies	
and	sequences	 that	would	otherwise	be	 the	subject	 to	restrictive	 intellectual	property	
rights	regimes	available	to	scientists	without	restriction.		
	
Whilst	 a	 share-waring	 commons	 ethos	 is	 now	 emerging	 as	 a	 key	 mode	 of	 exchange	
within	 the	 life	 sciences,	 proprietary	 modes	 of	 ownership	 have	 not	 disappeared	
altogether.	Rather,	as	a	number	of	scholars	have	recently	noted,	open	and	closed	models	
of	 innovative	 now	 often	 co-exist;	 albeit	 in	 sometimes	 contradictory	 and	 uneasy	ways	













of	 protection	 is	 most	 effectively	 secured	 through	 the	 application	 an	 older	 form	 of	
intellectual	property	right	that	has,	to	date,	played	a	much	less	celebrated	but	I	would	











































                                                
9 Percy Schmeiser and Schmeiser Enterprises Limited v Monsanto Canada Incorporated and Monsanto 
Company[2004] 1 S.C.R. 902, 2004 SCC 34 at 156. available in full at Journal of Environmental Law (2005) 17 






























                                                
10 That could be cryopreserved and later generated into whole, experimental, knockout mice.  
































It	 thus	 became	 evident	 that	 it	 had	 become	wholly	 unproductive	 to	 view	model	mice	
simply	as	 ‘tangible	products’	 there	 to	be	maximally	commercialized	without	regard	 to	
the	impact	monopolisation	may	have	on	other	researchers.	Rather	than	being	seen	as	a	
finished	 ‘product’	 to	be	 covetously	 controlled	 as	 a	 single	piece	of	 tangible	 intellectual	
property,	the	engineered	mouse	and	mouse	model	colonies	from	which	they	are	drawn	
became	 constituted	 not	 just	 as	 a	 set	 of	 essential	 research	 tools,	 but	 rather	 as	 a	 vital	
experimental	space	or	operative	environment	within	which	to	continually	experiment	on	
the	 ‘software’	 of	mammalian	 genetics	 and	 phenotypical	 associations	 (see	 also	Davies,	
2012;	2013).	In	order	to	explicate	all	the	changes	that	are	induced	in	the	mouse	through	
each	 experiment	 they	 need	 to	 be	 bred	 again	 to	 establish	 the	 effects	 of	 removing	 or	






a	 referential	 anchor	 but	 must	 therefore,	 be	 capable	 of	 being	 widely	 circulated	 and	
reproduced	time	and	again	with	no	loss	of	fidelity.	This	provides	the	essential	‘common	
ground’	 for	 communal	 experimentation.	 Whilst	 computer	 program	 platforms	 are	
amenable	 to	 this	 kind	 of	 replication,	 mice,	 though	 humble	 creatures,	 are	 not	 so	





are	more	 subtle	 and	difficult	 to	 detect	 and	 this	 is	 highly	 problematic	 for	 researchers.	


















                                                
12 Genetic drift describes random fluctuations in the numbers of gene variants in a population and takes place 
when the occurrence of variant forms of a gene, called alleles, increases and decreases by chance over time. It 
usually occurs in small populations, where infrequently occurring alleles face a greater chance of being lost. 
Once it begins, genetic drift will continue until the involved allele is either lost by a population or until it is the 









Protection	of	brand	 identity	has	a	 long	history	 in	 corporate	development.	Historically	
the	 trademark	 performed	 the	 function	 of	 associating	 manufactured	 goods	 with	 their	
owners	 and	 originators.	 As	 Schecter	 (1925:21)	 notes	 in	 his	 seminal	 treatise	 on	 the	
history	of	trademarks,	until	the	early	medieval	period	the	trademark	performed	a	dual	
function	 as	 both	 “personal	 or	 proprietary	 mark’	 and	 ‘production	 mark’	 assuring	 the	
quality	 of	 the	 good	 through	 direct	 association	with	 the	 personal	 qualities	 or	 identity,	
indeed	 the	reputation,	of	 the	maker”.	As	 I	hope	 to	have	explicated	here,	model	mouse	
development	at	Jackson	had	its	genesis	within	a	tradition	of	crafted	production	amongst	
mouse	 fanciers	 that	 was	 itself	 located	 within	 a	 wider	 heritage	 and	 economy	 of	
craftworking	and	craftsmanship	that	existed	in	Maine	at	that	time.13	The	earliest	strains	
of	 inbred	 mice	 that	 were	 accessioned	 to	 Jackson	 were	 very	 much	 a	 product	 of	 this	
tradition	 in	 the	 late	 1930s.	 The	 advent	 of	 mass	 production	 typically	 results	 in	 the	
detachment	of	the	maker	(him	or	herself)	from	the	manufactured	product.	At	this	point	




provenance	 (source	 of	 origin	 of	 goods	 or	 service);	 to	 encapsulate	 complex,	 but	
unobservable	 information	 about	 the	 quality	 or	 characteristics	 of	 said	 products	 at	 a	
                                                








of	 IPR	 law	 in	 that	 they	 encourage	 (ultimately)	 disclosure	 of	 knowledge	 about	 the	
evolution	 of	 methods	 of	 production	 and	 prevent	 others	 from	 free	 riding	 on	 the	




“the	 brand	may	be	 all	 that	matters:	when	 trademarks	 protect	 brands	with	 significant	
reputational	 value,	 the	 brand,	 in	 and	 of	 itself,	 becomes	 a	 product	 characteristic	 that	
consumers	care	about	but	that	competitors	cannot	copy”	(WIPO,	2013:	86).	In	this	sense	
it	 becomes	 perhaps	 the	 most	 sophisticated	 mechanism	 for	 protecting	 IPR	 in	 the	
commons	environment.		
	
In	 some	 instances,	 trademarks	 themselves	 are	 allowed	 to	 evolve	 spontaneously	 over	
time.	An	example	of	a	corporate	brand	that	has	undergone	its	own	kind	of	‘genetic	drift’	
is	 that	of	 the	 iconic	American	cake	maker,	Betty	Crocker.	Beginning	as	a	stereotypical	
WASP	 in	 1933,	 Betty’s	 identity	 has	 been	 progressively	 reinvented	 to	 reflect	 the	
changing	genetic	constitution	of	those	identified	as	consumers	of	the	brand,	morphing	
slowly	to	become	variously	more	Afro	Caribbean,	Asian	and	Indian	(See	Fig.	1	and	also	
Marks,	 2007).	 This	 is	 a	 transmutation	 that	 has	 produced	 economic	 value	 for	 the	
company	 who	 have	 utilised	 it	 to	 continually	 update	 and	 refresh	 their	 brand.	 More	
26 
 






From	 its	 inception,	but	particularly	given	concerns	 raised	over	 the	constraining	effect	
that	 patents	 could	 have	 on	 research	 activity,	 Jackson	 had	 articulated	 an	 institutional	
commitment	 to	 circulate	 inbred	 or	 engineered	 mice	 free	 of	 patent	 and	 licensing	
demands.	As	C.C.	Little	was	 to	 comment	 retrospectively:	 “we	could	have	monopolised	
these	mice	…we	could	have	sent	out	only	mice	of	one	sex	or	strain	but	we	said	…	 ‘we	
shall	 share	 these	mice	with	everybody	 that	we	can’	 (cited	 in	Rader,	2004:	257).	From	
the	1930s	onwards,	JAX	began	to	supply	mice	to	a	wide	range	of	users	for	research	and	
general	 medical	 use,	 but	 from	 1938	 onwards	 also	 began	 to	 produce	 codified	
compendiums	 of	 highly	 detailed	 biological	 information	 about	 these	 strains.	 This	
effectively	 stabilized	 and	 made	 accessible	 tacit	 information	 formerly	 shared	 only	
amongst	 JAX	 researchers,	 technicians	 and	 their	 associates.	 The	 mice	 they	 were	






































CIEA,	 rather	 astonishingly,	 bought	 a	 patent	 infringement	 case	 against	 Jackson	 for	
distributing	 a	 strain	 of	 genetically	 modified	 mouse,	 the	 NSG,	 that	 they	 asserted	 was	
‘equivalent’	 to	the	NOG.15	The	NSG	was	an	unpatented	engineered	 	strain	that	 Jackson	
had	circulated	to	over	640	research	institutes	worldwide	for	experimental	use.	Jackson	
had	 developed	 their	 NSG	 mouse	 from	 their	 existing	 NOD-SCID	 strains.	 It	 was	 these	
strains	 that	 had	been	previously	 circulated	 to	 the	CIEA	where	 they	had	been	 crossed	
with	other	 strains	 to	produce	 the	NOG	mouse.	Both	 the	NOG	and	 the	NSG	were,	 thus,	
both	 created	 from	 NOD-SCID	 strains	 just	 via	 different	 processes.	 Outraged	 by	 this	
‘property	grab’	the	NIH	instructed	Jackson	to	counter	sue,	arguing	that	the	CIEA	were,	in	








Such	 incidents	 reflect	 the	difficulties	 Jackson	has	 experienced	 in	 regulating	 the	use	of	
their	resources	in	an	open	source	genetic	commons.	How,	in	such	circumstances	could	
they	 protect	 the	 stability,	 reputation	 and	 integrity	 of	 their	mammalian	 research	 tools	
and	corporate	brand	whilst	still	maintaining	the	ability	to	monetise	their	inventions?	As	
Stephen	 Hilgartner	 has	 recently	 argued	 (2017:	 17-19)	 although	 knowledge-control	
                                                
14 The CIEA was intending to circulate the NOG under highly restrictive terms: purchasers were prohibited from 
breeding or cross-breeding them whilst extensive 'reach-through' rights controlled successive work done with 
the mice. 
15 For a full analysis see Abbott, 2009.  
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regimes	 such	 as	 IPR	 “may	 attempt	 to	 ‘pre-package’	 a	 limited	 set	 of	 modes	 of	
engagement”	(by,	for	example,	normalising	patent	as	the	preferred	mode	of	protection	
for	biological	 inventions)	 scientific	 actors	have	often	proven	 to	be	extremely	adept	at	
selectively	 adopting	 “several	 regimes	 at	 once,	 or	…	 several	 regimes	 in	 succession”,	 to	
advance	 their	 interests.	 	 They	 may	 also,	 he	 notes,	 “try	 to	 construct	 new	 knowledge-
control	 regimes	 by	 recombining	 elements	 of	 existing	 ones	 –	 as	 in	 the	 well-known	
example	 of	 the	 General	 Public	 License,	 which	 uses	 copyright	 and	 contract	 law	 to	
constitute	 a	 novel	 “free-software”	 regime”.	 In	 response	 to	 these	 challenges	 JAX’s	
community	 of	 	 researchers	 began	 to	 undertake	 just	 this	 kind	 of	 similarly	 provocative	
ontological	work.	By	selectively	combining	process	patents	with	trademark	they	quietly	




If	 Jackson	 were	 not	 insisting	 that	 accessioned	 mice	 be	 patented,	 nor	 consequently	
receiving	any	percentage	of	 royalties	obtained	 for	 their	use,	how	would	 it	be	possible	
for	them	to	create	a	continued	revenue	stream	from	their	production	and	distribution	
and	thus	maintain	 their	 institutional	viability?	 	The	answer	 I,	believe,	 lies	 in	 the	value	
that	 attaches	 to	 standardisation,	 consistency	 and	 reputational	 capital	 in	 laboratory	
experimentation.	Whilst	the	Betty	Crocker	Corporation	has	been	able	to	make	 ‘genetic	
drift’	 in	 their	brand	 identity	work	 for	 them	in	economically	generative	ways,	 for	a	 lab	
such	 as	 Jackson	 it	 only	 poses	 a	 threat	 to	 production	 quality.	 Random	 variations	 in	
production	 introduce	 inconsistencies	 that	 jeopardize	research	experiments	by	making	
replicability	 complex	 if	 not	 impossible.	Genetic	drift	 in	mutant	mouse	 colonies	occurs	




substrain	 divergence	 can	 confound	 research	 conclusions	 making	 them	 inaccurate,	
misleading	and	sometimes,	unusable”.16		
	
Consistency	 in	 manufacture	 and	 reliability	 are,	 therefore,	 the	 hallmarks	 of	
craftsmanship	 in	 model	 mouse	 production.	 JAX®Mice	 have	 these	 qualities	 and	 the	
brand	has	become	highly	valorised	and	valued	as	a	consequence.	How	though	to	protect	
this	 brand	 from	 becoming	 besmirched	 by	 unlicensed	 and	 potentially	 shoddy	
reproduction?	 JAX	 has	 resolved	 this	 dilemma,	 which	 confronts	 all	 producers	 of	
trademarked	works	 in	open	 source	 economies,	 through	 the	development	of	 a	unique,	
and	 (somewhat	 surprisingly)	 patented	 process.	 For	 while	 the	 management	 of	 the	
Jackson	Laboratory	have	always	been	philosophically	opposed	to	‘product	patents’	they	
are	 willing	 to	 accommodate	 what	 are	 termed	 ‘process	 patents’,	 in	 the	 interest	 of	
protecting	 a	 particular	 attribute	 or	 quality,	 one	 that	 is,	 in	 my	 view,	 becoming	




the	 integrity	 of	 the	 Lab’s	 resources	 by	 limiting	 cumulative	 genetic	 drift.	 It	 does	 so	 by	
literally	 ‘revitalizing’	 these	strains	with	new	genetic	material.	This	system	enables	 the	
production	 colonies	 to	 be	 literally	 “re-booted’,	 as	 Jackson	 puts	 it,	 with	 cryogenically	
preserved	embryos	or	gametes	from	specially	prepared	stocks,	every	five	generations.	
This	 refreshment	 effectively	 ‘freezes’	 or	 stabilizes	 the	 genetic	 profile	 of	 the	 mouse,	
                                                
16 https://www.jax.org/news-and-insights/jax-blog/2015/march/more-researchers-are-using-b6j-mice-than-ever-
before. The imperative to create the program arose from a number of important cases in which genetic drift or 
substrain divergence marred research experiments (See Bailey, 1982; Threadgill et.al, 1997, Specht and 
Schoepfer, 2001, and Stevens et.al 2007).  
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“stopping	 the	 accumulation	 of	 mutations	 and	 revolutionizing	 the	 uniformity	 of	 the	
mouse	as	a	research	tool”.17	The	stocks	are	set	up	to	give	a	25-year	supply	of	genetically	
consistent	 mouse	models.	 Process	 patents	 on	 the	 GSP	 technology	 ensure	 the	 genetic	




researchers	 at	 JAX.	 Although	 particular	 lines	 can	 be	 stabilized	 sufficiently	 to	 sustain	




associated	 reach	 through	 rights	 to	 valuable	 strains	 these	 individuals	 and	 the	 Jackson	
itself	 lose	 access	 to	 a	 vital	 revenue	 stream.	 This	 proves	 to	matter	 less	 than	might	 be	
imagined,	as	the	deft	application	of	what	Calvert	(2012:183)	terms	a	“diverse	ecology	of	
open	 and	 proprietary	 forms”	 (in	 this	 case	 a	 process	 patent	 on	 their	 Genetic	 Stability	
Program	and	the	trademarking	of	strains	produced	and	stabilized	through	such	means)	
has	 here	 combined	 to	 deliver	 a	 guarantee	 of	 quality	 that	 is	 simply	 unrivalled	 in	 the	
mouse	genetics	economy.	Consequently,	JAX®Mice	are	recognized	globally	as	the	‘gold	
standard’	mammalian	mouse	strains	and	models	 in	the	world.	Donors	are	prepared	to	
forgo	 patents	 on	 their	 invented	models	 (which	may	 actually	 deter	 use)	 and	 agree	 to	
open	 circulation	 if	 their	 model	 can	 be	 accessioned	 to	 a	 bank	 that	 will	 work	 hard	 to	
assure	 its	 continued	 integrity,	 and	 thus,	 reputational	 and	 economic	 value.	 As	 David	






leading	 mammalian	 genetics	 research	 institution	 with	 exceptional	 genetic	 quality	
control	and	comprehensive	mouse	data	bases,	as	 this	package	also	makes	 the	donors’	
mice	 more	 attractive	 to	 potential	 for-profit	 licensees”	 (my	 italics).18	 The	 guaranteed	
integrity	 and	 reliability	 of	 the	mice,	 and	 JAX’s	 unrivalled	 institutional	 reputation	 has	
boosted	production	and	driven	demand,	turning	it	into	a	global	market	leader	that	sells	
over	three	million	mutant	mice	per	year	to	researchers	across	the	world.	It	is	by	these	
means	 that	 it	 has	 been	 possible	 for	 Jackson’s	 researchers	 (internal	 and	 external)	 to	
disavow	product	patents,	meet	all	 the	ethical	principles	of	open	access	 to	mammalian	









academic	 research	 commons	 for	 mammalian	 genetic	 resources,	 but	 has	 to	 date	
remained	largely	unexplored.	Throughout	the	first	two	decades	of	the	biotechnological	
revolution	(from	the	mid	1980s	to	the	mid	2000s)	the	dictum	that	product	patents	were	
an	 essential	 tool	 for	 asserting	 and	 protecting	 the	 rights	 and	 income	 of	 inventors	 of	
engineered	organisms,	 became	not	 only	popular,	 but	 canonical.	 It	 has	 therefore,	 been	
                                                
18 Einhorn, D. (2008) Research Report to the National Institutes of Health Grant Number 5RO3 HG003766-01 
Unpublished: Courtesy of the author.  
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Drawing	 on	 an	 analysis	 of	 research	 undertaken	 within	 the	 Jackson	 Laboratory,	 and	
situating	 that	within	 broader	 theoretical	 discussions	 of	 craft	working	 and	 the	 impact	





individual	 mice	 as	 ‘finished	 products’	 was	 always,	 ultimately,	 going	 to	 have	 stifling	
effects	on	innovation	–	to	the	detriment	of	all.	Model	mice,	 including	JAX®Mice	are,	 in	
this	context,	perhaps	best	conceptualised	as	collectively	authored	performative	works	







the	 experimental	 techniques	 that	 assure	 its	 continued	 integrity	 and	 thus,	
epistemological	and	economic	value	in	laboratory	settings	and	in	the	bioeconomy	more	
generally.	 Process	 patents	 have	 been	 deployed	 to	 protect	 the	 means	 of	 delivering	









Such	developments	perhaps	 invite	us	 to	reflect	 finally	on	 the	question	of	what	 the	re-
valorisation	 of	 trademark	might	 say,	 in	 this	 context,	 about	 other	 kinds	 of	 ontological	
drift	–	the	drift	for	example	that	is	evidenced	in	the	way	we	conceptualise	these	mice.	It	
would	 seem	 that	 the	 model	 mouse	 is	 now	 becoming	 ‘humanised’	 at	 more	 than	 a	
molecular	genetic	level.	No	longer	characterised	simply	as	technological	research	‘tools’	
model	mice	 seem	 now	 to	 be	 acquiring	 identities,	 legal	 personalities,	 reputations,	 and	
‘careers’	 that	 are	 singular,	 and	 require	 promotion	 and	 active	 protection	 from	
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